United Therapeutics Corporation cash flow to debt ratio of 4.15K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

United Therapeutics Corporation's free cash flow has decreased 3.69% from $1.08B last year to $1.04B, signaling decreasing performance

United Therapeutics Corporation's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

United Therapeutics Corporation's debt has decreased relative to shareholder equity from 0.05 last year to 0.00 today, signaling strengthened financials

United Therapeutics Corporation has a net cash position, so leverage is healthy.

United Therapeutics Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

United Therapeutics Corporation's profit margin has increased (0.05%) in the last year from 41.53% to 41.56%, signaling increasing performance

United Therapeutics Corporation's short-term assets of $3.70B exceed its short-term liabilities of $560.60M

United Therapeutics Corporation's return on assets of 18.16% is higher than the 5.00% threshold, indicating efficient asset utilization

United Therapeutics Corporation's return on equity of 20.18%, is higher than 15.00%, indicating good performance

United Therapeutics Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

United Therapeutics Corporation had positive net income in 5 out of 5 years, indicating stable and consistent earnings

United Therapeutics Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

United Therapeutics Corporation has a free cash flow yield of 4.63%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

United Therapeutics Corporation's yearly earnings has increased 11.68% since last year from $1.20B to $1.33B, signaling increasing performance

United Therapeutics Corporation's yearly revenue has increased 10.61% since last year from $2.88B to $3.18B, signaling increasing performance

ROIC 17.69% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

United Therapeutics Corporation's 3-year revenue CAGR of 18.02% is positive, indicating growing revenue over the past 3 years

United Therapeutics Corporation had revenue growth in 5 out of 5 years, indicating consistent revenue performance

United Therapeutics Corporation had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

United Therapeutics Corporation is overvalued relative to its fair value price of 430.00 based on Discounted Cash Flow model

United Therapeutics Corporation has an earnings yield of 5.81%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

United Therapeutics Corporation is overvalued relative to its fair value price of 326.06 based on EBITDA multiple model

United Therapeutics Corporation has an EV/EBITDA ratio of 11.52x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

United Therapeutics Corporation is undervalued relative to its fair value price of 588.70 based on Earnings Fair Value model

United Therapeutics Corporation has a PEG-ratio under 1 which is considered undervalued

United Therapeutics Corporation has a price-to-book ratio of 3.53x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

United Therapeutics Corporation has a price-to-sales ratio of 7.15x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue